Therapeutic effects of 1,25-dihydroxyvitamin D3 on diabetes-induced liver complications in a rat model

LINA LIU¹, GUODONG LV², CONGHUA NING¹, YE YANG¹ and JUN ZHU¹

¹Department of Endocrinology; ²Institute of Research, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China

Received January 31, 2015; Accepted March 10, 2016

DOI: 10.3892/etm.2016.3242

Abstract. It has been suggested that 1,25-dihydroxyvitamin D3 (vitamin D) plays a protective role against inflammation and insulin resistance (IR) in type 2 diabetes mellitus (T2DM). The present study investigate the hypothesis that vitamin D may exert beneficial effects on the liver in a rat model of T2DM by regulating the expression of inflammation-related cytokines and ameliorating IR induced by inflammation. Normal control group rats were fed a basic diet (NC). Experimental rats received a high-fat diet for 8 weeks and were then injected with streptozotocin (STZ) to induce T2DM. Half of the T2DM model rats received vitamin D (0.03 µg/kg/day) for 8 weeks (vitamin D-treated group; VD; n=11), while the other (T2DM group; DM; n=10) and NC group received an equivalent quantity of peanut oil. Following sacrifice, fasting plasma glucose (FPG) and fasting insulin (FINS) were recorded and homeostasis model assessment of IR (HOMA-IR) was calculated. Liver histopathology was examined using hematoxylin and eosin staining. The levels of the inflammatory cytokines C-Jun N-terminal kinase, C-Jun, tumor necrosis factor-α and interleukin-1β were measured using immunohistology, quantitative polymerase chain reaction and western blot analyses. The results revealed that treatment with vitamin D markedly alleviated the pathological alterations of liver and reduced the expression of inflammatory cytokines at the protein and mRNA levels. Furthermore, decreased levels of FPG, HOMA-IR and increased FINS were detected. In conclusion, the results of the present study indicate that vitamin D has therapeutic effects on diabetes-induced liver complications in T2DM model rats, which may involve the modulation of the inflammatory response, attenuating the ‘crosstalk’ between inflammation and IR and ameliorating hyperglycemic state.

Introduction

The World Health Organization calculates that ~171 million individuals worldwide have diabetes, and that its prevalence will reach epidemic proportions by 2030, affecting ~366 million individuals (1). The increasing prevalence of diabetes represents a significant burden to human health due to its numerous and serious complications. It has been suggested that chronic low-intensity inflammation and insulin resistance (IR) are risk factors for type 2 diabetes mellitus (T2DM), and are involved in the initial onset of T2DM and the progression of its complications. Evidence from various directions, including observational and experimental studies, indicates the protective capacity of 1,25-dihydroxyvitamin D3 (active vitamin D) in chronic low-intensity inflammation and IR in T2DM and its complications. Although the underlying mechanism is yet to be clarified, it is recognized that this role may be at least partially associated with the immunological regulation of vitamin D, which is able to downregulate the production of proinflammatory cytokines (2). Previous studies have reported associations between vitamin D insufficiency and diseases related to an amplified inflammatory state, such as diabetes. The effects of vitamin D in downregulating the proinflammatory profile in T2DM patients may be implicated in the association between vitamin D deficiency and impaired glucose tolerance or T2DM that has been observed in humans (3), and in the protective effects of vitamin D supplementation (4).

Diabetes-induced liver complications are characterized by varying degrees of inflammation, fatty degeneration, fibrosis and other pathological changes. Current studies regarding the effects of vitamin D on diabetes-induced liver complications and its potential mechanisms in T2DM are seldom reported. In consideration of the protective role of vitamin D against inflammation and IR in T2DM, we hypothesized that the cytokines or molecules involved in inflammation and IR in T2DM may be targets of vitamin D. The present study was conducted to test the hypothesis that vitamin D may improve the diabetes-induced liver complications by suppressing the expression of inflammation cytokines including C-Jun N-terminal kinase (JNK), C-Jun, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in rat models of T2DM, thus determining the association, if any, between vitamin D, inflammation and diabetes-induced liver complications. Investigations into the targets of vitamin D may provide insight...
into the potential therapeutic mechanism of diabetes-induced liver complications.

Materials and methods

Animal modeling and grouping. A total of 34 male Sprague-Dawley rats (specific pathogen-free; weight, 280±10 g; age, 8 weeks) were provided by the Xinjiang Center for Disease Control and Prevention (Urumqi, China). The rats were housed in individual cages maintained under ambient temperature (25±2°C) and had ad libitum access to water and food. After a week of acclimation, rats were randomly divided into two groups: Normal control (NC; n=10) and T2DM model (n=24) groups. The T2DM rat model was established by administering a high-fat and high-sugar diet (containing 10% refined lard, 20% sucrose, 2% cholesterol, 8% custard powder and 60% of normal diet; supplied by the Institute of Research in Xinjiang Medical University, Urumqi, China) for 8 weeks. Subsequently, the rats received a peritoneal injection of 35 mg/kg streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO, USA) in 0.1 mol/l citrate buffer (pH 4.2; Weber Liyang Chemical Group, Xi’an, China), while the NC group rats were fed the basic diet and received citrate buffer alone. One week later, random non-fasting blood glucose was measured from tail blood samples using a portable glucometer (Accu-Chek, Mannheim, Germany). Diabetes was determined by the presence of hyperglycemia (random non-fasting glucose level, >16.7 mmol/l). Among the initial 24 rats in the T2DM model group, 22 met the hyperglycemia criteria. Then, half of the T2DM model rats (n=12) were randomly allocated to the vitamin D-treated group (VD; n=11), and each rat was administered vitamin D (0.03 µg/kg/day; Shanghai Roche Pharmaceutical Ltd., Shanghai, China) by filling the stomach using a lavage needle (insertion depth, ~5 cm) for 8 weeks, while the other 11 rats (T2DM group; DM) and the NC group received an equivalent administration of peanut oil (Shandong Luhua Group Co., Ltd., Shandong, China) daily for 8 weeks. During the experimental period, the NC group was fed the basic diet, while the DM and VD groups were fed the high-fat and high-sugar diet. At the end of the experiment, the NC and VD groups had retained 10 rats each, while 9 rats remained in the DM group. The study was approved by the ethics committee of Xinjiang Medical University.

Tissue sampling and preparation. Following the trial, the rats were sacrificed using 2% sodium pentobarbital injection (50 mg/kg; Merck Millipore, Darmstadt, Germany). The serum and liver specimens were harvested. Blood samples were collected from the abdominal aorta and were centrifuged at 990 x g for 20 min (5430R centrifuge; Eppendorf, Hamburg, Germany) to separate the plasma for use in assays. The serum levels of fasting plasma glucose (FPG) and fasting insulin (FINS) were detected using a modular chemical analyzer (7600; Hitachi, Tokyo, Japan) and an Architect i2000SR immunoassay analyzer (Abbott Laboratories, Lake Bluff, IL, USA), respectively. HOMA-IR was calculated using the following formula: (FPG x FINS)/22.5. Liver tissues were cut into small pieces, immersed into RNAlater Stabilization Solution (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and stored at -80°C for subsequent reverse transcription quantitative-polymerase chain reaction (RT-qPCR) and western blot analyses. Remaining liver tissues were fixed in 4% paraformaldehyde (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and stored at 4°C for hematoxylin and eosin (H&E; Shun Tian Biological, Ltd., Shanghai, China) staining and immunohistochemistry.

Histopatological staining. Fresh liver tissues were washed with saline, and fixed in 4% paraformaldehyde. Following dehydration these tissues were embedded in paraffin, and then cut into 5-µm sections using a microtome (Leica Biosystems Nussloch GmbH, Nussloch, Germany). Liver tissues from all rats were subjected to routine histological examination. The sections were mounted on glass slides and deplated of paraffin using xylene (Weber Liyang Chemical Group). Then, sections were subjected to H&E staining. The sections were observed using a digital image-capture system (DM300B; Leica Microsystems).

Immunohistochemistry. Serial sections of 5 µm thickness were cut from paraffin-embedded tissue blocks and placed onto glass slides. After drying for 2 h, paraffin sections were deparaffinized and hydrated through a series of graded alcohol. Endogenous peroxidase activity was inactivated with 0.3% hydrogen peroxide. For antigen retrieval, the glass slides were immersed in citrate buffer (0.01 M) at 95°C for 20 min, and refrigerated at room temperature. Tissue slices were incubated with rabbit anti-rat antibodies against C-Jun (bs-0670R; 1:100; Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China), JNK, TNF-α and IL-1β (BA1648, BA0131 and BA2782; 1:100; Wuhan Boster Biological Technology, Ltd., Wuhan, China) respectively at 4°C overnight. Then secondary antibody (5:100; ZLI-9017; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) was added to incubate the slices for 20 min at room temperature. After staining with 3,3'-diaminobenzidine chromogenic reagent (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) and counterstained with hematoxylin for 5-10 min. The slices were sealed and visualized by microscopy using a digital image-capture system (DM300B; Leica Microsystems). Brown staining was considered to indicate positive detection. A negative control was performed by omitting the primary antibody. The intensity of staining was evaluated semi-quantitatively in five random microscopic fields under high magnification (x400). The scoring criteria were based on the percentage of positive area and the staining intensity. The percentage of positive area was scored as follows: No positive staining was scored as 0 points; <25% as 1 points; 25-50% as 2 points; 51-75% as 3 points; and >75% as 4 points. The staining intensity was scored as 0-3 points, representing negative, weak, moderate and strong staining, respectively. Five fields of each section were evaluated and the average scores for each parameter were calculated, then added. Zero points can be defined as negative (-), 2-3 points were divided into weakly positive (+); 4-5 points were divided into medium positive (++; and 6-7 points were divided into strong positive (+++).

RT-qPCR. Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentrations of total RNA were measured by absorbance at 260/280 nm (MD1000; Beijing Thmorgan Biotechnology Co., Ltd., Beijing, China). Prior to reverse transcription, gDNA eraser (Qiagen) was used
Western blot analysis. Total protein was extracted from liver tissues using radioimmunoprecipitation assay (RIPA) buffer (containing 0.1% PMSF), and the proteins were collected by centrifuging at 20,660 x g at 4°C for 10 min. As the protein phosphorylation was reversible and would be dephosphorylated by phosphatase, there was need to suppress or avoid cell phosphatase of endogenous and exogenous disturbances in the process of sample preparation and the immune detection, by using phosphatase inhibitor and protease inhibitor to draw reliable conclusions. Phosphatase inhibitor and protease inhibitor (Thermo Fisher Scientific, Inc.) were added to RIPA buffer (Thermo Fisher Scientific, Inc.) according to manufacturer’s instructions. Protein concentrations were quantified using a bicinchninic protein assay with bovine serum albumin as the standard (both purchased from Thermo Fisher Scientific, Inc.). Equal quantities of protein (50 µg) were separated by 10% SDS-PAGE (Beijing Solarbio Science & Technology, Co., Ltd.) and electrotransferred to polyvinylidene fluoride membranes (Roche AG, Basel, Switzerland). The membranes were blocked with 5% nonfat skim milk in Tris-buffered saline containing 0.1% Tween 20 (TBST; Beijing Solarbio Science & Technology Co., Ltd.) for 1 h at room temperature and then incubated overnight at 4°C with polyclonal rat anti-rabbit antibodies against JNK (cat. no. 9258S), phospho-JNK (cat. no. 4671S), C-Jun (cat. no. 9165S) and phospho-C-Jun (cat. no. 2361S) (all 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) then washed with TBST. Following this, membranes were incubated with secondary anti-rabbit antibody solution (1:1,000; Cell Signaling Technology, Inc.) overnight at 4°C with polyclonal rat anti-rabbit antibodies (Roche AG, Basel, Switzerland). The membranes were blocked with 5% nonfat skim milk in Tris-buffered saline containing 0.1% Tween 20 (TBST; Beijing Solarbio Science & Technology Co., Ltd.) for 1 h at room temperature and then incubated overnight at 4°C with polyclonal rat anti-rabbit antibodies against JNK (cat. no. 9258S), phospho-JNK (cat. no. 4671S), C-Jun (cat. no. 9165S) and phospho-C-Jun (cat. no. 2361S) (all 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) then washed with TBST. Following this, membranes were incubated with secondary anti-rabbit antibody solution (1:1,000; cat. no. 1450236; Invitrogen; Thermo Fisher Scientific, Inc.) for 2 h at room temperature, and washed with TBST. Expression levels of the targeted proteins were detected using BCIP/NBT chromogenic substrate (Invitrogen; Thermo Fisher Scientific, Inc.). Protein concentrations were quantified using a bicinchoninic protein assay kit. The intensity of each band was captured digitally and measured using Quantity One software (Bio-Rad Laboratories, Inc.).
Table II. Biochemical parameters.

| Group      | FPG (mmol/l) | FINS (mIU/l) | HOMA-IR |
|------------|--------------|--------------|---------|
| NC (n=10)  | 5.80±0.94    | 19.49±1.53   | 5.01±0.81|
| DM (n=9)   | 24.66±2.47   | 11.81±1.36   | 12.86±1.33|
| VD (n=10)  | 20.39±2.12   | 13.07±1.15   | 11.77±0.80 |
| F-value    | 153.214      | 59.724       | 78.73   |

\(^aP<0.01\) vs. NC group; \(^bP<0.01\) vs. DM group. FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; NC, normal control group; DM, type 2 diabetes mellitus group; VD, vitamin D-treated group.

Discussion

It has been demonstrated that inflammation and IR play an initial role in the onset of T2DM, and that the progression of its complications, suggesting that the regulation of inflammation and IR may inhibit the emergence and progression of this disease. Vitamin D is a well-known steroid hormone that has been identified as a regulator of inflammation and IR. Based on available clinical and epidemiological data, the positive effects of vitamin D appear to be primarily related to its action on inflammation and secondary to its action on insulin sensitivity and secretion.

In the present study, H&E staining and immunohistochemistry were performed to assess the direct effects of vitamin D on diabetes-induced liver complications. The results showed that the administration of vitamin D significantly alleviated certain pathological changes, particularly steatosis and inflammatory cell infiltration. Furthermore, immunohistochemistry and RT-qPCR analysis showed that the expression levels of JNK, C-Jun, TNF-α and IL-1β, which are implicated in inflammation and IR, were decreased following treatment with vitamin D. Based on these results, we speculate that vitamin D exerts therapeutic effects on diabetes-induced liver complications, possibly by down-regulating the expression of JNK, C-Jun, TNF-α and IL-1β. This modulation may be in part due to the anti-inflammatory effects of vitamin D on diabetes-induced liver complications, possibly by down-regulating the expression of JNK, C-Jun, TNF-α and IL-1β. The mRNA expression levels of JNK, C-Jun, TNF-α and IL-1β in the NC group were relatively low, and were significantly elevated in the DM group (P<0.01). Compared with the DM group, vitamin D treatment appeared to significantly decrease the expression levels of the target mRNAs (P<0.01) (Table V).
properties of vitamin D; however, the underlying mechanism remains to be elucidated.

A previous study suggested that the activation of inflammatory pathways interferes with normal metabolism and disrupts insulin signaling (6). The presence of chronic inflammatory diseases, such as rheumatoid arthritis or hepatitis, significantly increases the risk for the development of IR and/or T2DM, thus suggesting an association between chronic inflammatory state and impaired insulin activity (7,8). In addition, prior results have indicated that vitamin D improves insulin sensitivity by its anti-inflammatory activity. Incubation of isolated monocytes with vitamin D attenuated the expression levels of proinflammatory cytokines involved in IR, such as IL-1β, IL-6 and TNF-α in patients with T2DM (9). Similarly in the present study, in liver the tissues of T2DM model rats the levels of IL-1β and TNF-α were decreased following the administration
of vitamin D, which was accompanied by an improvement in HOMA-IR. Thus, we speculate that vitamin D is able to interfere with the crosstalk between inflammation and IR.

Targher et al (10) demonstrated that the beneficial effects of vitamin D were mediated through the modulation of VDR, a receptor of vitamin D, thereby improving signal transduction in the treatment of diabetes-induced liver complications. VDR is constitutively expressed by immune cells, which suggests that vitamin D plays an important role in the modulation of the inflammatory response. The liver contains a large quantity of Kupffer cells, which may be activated and release a wide range of products implicated in liver injury, such as inflammatory cytokines including TNF-β. These factors may further exacerbate hepatic inflammation and IR, as found in the present study, disabling the inflammatory pathway within these cells prevented the generalization of inflammation and IR (11). VDR is almost universally expressed in nucleated cells (12), in which it controls vital genes associated with bone metabolism, chronic diseases and inflammation. Therefore, in the present study we hypothesized that cells exhibiting VDR may be a target of vitamin D. It has been demonstrated in monocytes, dendritic cells and T cells that vitamin D is able to inhibit the expression of inflammation-related genes by interacting with the NF-kB and AP-1/C-Jun pathways (13). In the present study, vitamin D appeared to downregulate the expression of C-Jun and its upstream signaling molecule JNK in liver tissues.

JNKs were initially described as a family of serine/threonine protein kinases, and may be activated by diverse stimuli including cytokines (such as TNF-α and IL-1β), reactive oxygen species, endoplasmic reticulum stress, free fatty acid, hyperglycemia and advanced glycation end products, all of which are known to be increased under diabetic conditions (14). JNK serves a crucial function in chronic inflammatory diseases involving the expression of specific proteases and cytokines (15). JNK activity and/or expression levels are elevated in various tissues in patients with T2DM, and have been shown to promote the progression of inflammation and IR in T2DM and its complications, which is in accordance with the present results. The specific function of JNK in the dysregulation of hepatic insulin signaling has also been demonstrated. Previous studies have indicated that hepatic inhibition of JNK using a dominant-negative protein or knockdown of JNK in diabetic mice significantly lowered blood glucose levels and improved insulin sensitivity. Silencing of hepatic JNK by small interfering RNA increased the expression of glycolysis enzymes, reduced the expression of gluconeogenic enzymes and the attenuated development of IR in a nutritionally-induced diabetes mouse model (16). These results directly demonstrate the therapeutic potential of JNK inhibitors in diabetes. On the basis of the present results, vitamin D may function as an inhibitor of JNK. Activated JNK is able to directly target insulin receptor substrate 1 (IRS)-1 for serine phosphorylation, which inhibits the insulin signaling cascade (17). In addition, Sharfi and Eldar-Finkelman (18) showed that the expression level of JNK is markedly elevated in the diabetic liver and that JNK/GSK-3-mediated phosphorylation of IRS-2 inhibited insulin signaling in liver cells. Thus, JNK has been viewed as a potential target for the prevention and treatment of T2DM (19).

At least 50 proteins have been identified as JNK substrates. Among these substrates, C-Jun is a representative target, as the functions of JNK depend largely on phosphorylating C-Jun (20). Phosphorylated JNK translocates into the nucleus and regulates downstream transcriptional programs via

Table IV. Immunohistochemical staining for TNF-α and IL-1β protein expression levels in the rat liver tissues.

| Group    | -     | +     | ++    | +++   | -     | +     | ++    | +++   |
|----------|-------|-------|-------|-------|-------|-------|-------|-------|
| NC (n=10)| 7     | 3     | 0     | 0     | 8     | 2     | 0     | 0     |
| DM (n=9) | 0     | 0     | 3     | 6     | 0     | 1     | 1     | 7     |
| VD (n=10)| 1     | 4     | 4     | 1     | 2     | 3     | 4     | 1     |

Table V. Reverse transcription-quantitative polymerase chain reaction analysis of mRNA expression levels.

| Group    | JNK     | C-Jun   | TNF-α     | IL-1β     |
|----------|---------|---------|-----------|-----------|
| NC (n=10)| 1.02±0.11 | 0.90±0.12 | 0.82±0.09 | 0.77±0.09 |
| DM (n=9) | 7.39±1.27<sup>a</sup> | 5.15±0.98<sup>a</sup> | 6.14±1.13<sup>a</sup> | 6.31±1.33<sup>a</sup> |
| VD (n=10)| 5.93±1.29<sup>b</sup> | 3.76±0.97<sup>b</sup> | 4.78±1.07<sup>b</sup> | 5.09±0.84<sup>b</sup> |
| F-value  | 99.707 | 72.906 | 62.305 | 55.018 |

<sup>a</sup>P<0.01 vs. NC group; <sup>b</sup>P<0.01 vs. DM group; JNK, C-Jun, N-terminal kinase; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; NC, normal control group; DM, type 2 diabetes mellitus group; VD, vitamin D-treated group.
transcription factor C-Jun, and consequently promotes the activity of the activator protein-1 (AP-1). This promotion may result in the increased expression of proinflammatory cytokines, such as IL-1β, IL-6 and TNF-α. These cytokines target cell membrane receptors, thus exacerbating the inflammatory response and inducing IR (21). In addition to being leaner and more insulin responsive, high-fat diet-fed JNK⁻/-mice exhibited reduced expression of inflammatory cytokines such as IL-6, TNF-α and MCP-1 (22).

Among the best-studied pathways leading to JNK activation is TNF-α signaling via TNF-α receptor 1 (TNFR1) (23). Mice that lack TNFR1 and rats injected with an antibody against TNF-α exhibit reduced liver activation of JNK and C-Jun/AP-1 (24). Notably, JNK expression has been implicated in hepatocyte injury mediated by TNF-α (25). In hepatocytes, TNF-α rapidly activates JNK, leading to the activation of C-Jun/AP-1 and consequently the production of proinflammatory cytokines, particularly TNF-α and IL-1β, which in return activate JNK as has been noted. In conclusion, the interaction between JNK and TNF-α forms a vicious circle and results in increased expression of inflammatory cytokines, which exacerbated inflammation and IR in liver tissues in the present study. The administration of vitamin D has been shown to inhibit the inflammatory response of diabetic mice and reduce fasting glucose and serum TNF-α levels (26). Vitamin D administration also inhibited the expression of TNF-α in monocytes extracted from diabetic patients (9). Furthermore, TNF-α is hypothesized to play a major role in the pathophysiology of IR in rodents (27) via the phosphorylation of IRS-1 protein on serine residues. Recombinant TNF-α decreases insulin sensitivity, while TNF-α or TNF-α receptor null mice exhibit an increased sensitivity in response to this hormone, suggesting a direct role for TNF-α in the development of IR.

In chronic liver disease, the overproduction of IL-1β and TNF-α is observed (28). Negrin et al. (29) reported that the development of hepatic steatosis required IL-1β signaling, which upregulated fatty acid synthase to promote hepatic lipogenesis. Furthermore, the administration of IL-1β receptor antagonist to obese mice markedly reduced steatosis in hepatic tissues. IL-1β binding to IL-1β receptor 1 (IL-1RI) activated a number of inflammatory pathways, including JNK, which induced IR by attenuating IRS-1 activation while activating C-Jun/AP-1 and consequently inducing the transcription of inflammatory genes including itself (24), similarly to TNF-α, ultimately resulting in extensive inflammation reactions in the liver. IL-1RI⁻/⁻ were protected against high-fat diet-induced IR. Recent clinical studies aimed at attenuating IL-1β activity in subjects with T2DM have yielded promising results;
demonstrating improvements in hyperglycaemia, insulin secretion and sensitivity, β-cell function and reduced levels of systemic inflammation (30). Moore et al (31) suggested that the anti-inflammatory effect of vitamin D3 derived from its ability to downregulate the IL-1β-induced activation of JNK in microglial cells.

It is currently unclear whether JNK is the cause or effect of other cytokines, particularly TNF-α and IL-1β. The targeting of individual inflammatory cytokines may not be highly effective, whereas the targeting of inflammatory kinases JNK generated a robust anti-diabetic action as this factor integrated signals from multiple inflammatory mediators. Therefore, targeting JNK could potentially disable the inflammatory response and improve insulin action (32). For example, TNF-α is a key downstream effectors of JNK-mediated IR in 3T3-L1 adipocytes (33). In the present study, the protein expression levels of JNK and C-Jun, in addition to their active forms phospho-JNK and phospho-C-Jun, were evaluated using western blot assays. The results showed that compared with the DM group, vitamin D was able to downregulate the protein expression of JNK and C-Jun, their active forms and the ratios of phospho-JNK/JNK and phospho-C-Jun/C-Jun. These results suggested that vitamin D was able to regulate the phosphorylation of JNK and C-Jun. Notably, increased dietary vitamin D was beneficial in preventing inflammation-associated colon cancer via the suppression of inflammatory responses, particularly JNK (34). Supplementation with vitamin D improved IR in muscle cells by reducing the phosphorylation of JNK (35). These results suggest that vitamin D has a crucial impact on inflammation and IR induced by JNK. Thus, JNK signaling pathway may be a crucial target of vitamin D with regard to anti-inflammation and improves IR in diabetes-induced liver complications. Hence, the inhibition of the JNK pathway prevents its activation by various stimuli, particularly TNF-α and IL-1β, and contributes to the reduced production of pro-inflammatory cytokines in the liver. In conclusion, vitamin D may play a role in attenuating the positive feedback loop between JNK signaling pathway and TNF-α and IL-1β, thus ameliorating the diabetes-induce liver complications in T2DM model rats.

Lipid infusion or high fat feeding promotes IR in rodents and humans (33). IR occurs in the liver and other tissues, resulting in metabolism disturbance which may result in the accumulation of fat in hepatocytes. Notably, the Third National Health and Nutrition Examination Survey identified an inverse association between vitamin D status and IR/diabetes (36). Significant improvements were observed in insulin sensitivity and IR in a randomized, controlled, double-blind intervention, which involved the administration of 100 µg vitamin D (4,000 IU) for 6 months to South Asian women who were insulin resistant (HOMA-IR, >1.93; serum 25(OH)D, <50 nmol/l) (37), which was in agreement with the present findings. In the present study, the HOMA-IR in the DM group was significant higher compared with the NC group following vitamin D treatment, thus showing a tendency toward improvement. Although the underlying mechanisms remain unclear, it may partly due to the anti-inflammatory properties of vitamin D. The JNK-C-Jun axes is a major inflammatory pathway involved in the disruption of insulin signaling, and modulating its action with anti-inflammatory agent is believed to improve insulin sensitivity and glucose homeostasis (38). In the present study, vitamin D may have served as the anti-inflammatory agent in regulating JNK/C-Jun, TNF-α and IL-1β in insulin signaling.

It has been reported that the combination of lipotoxicity and glucotoxicity induced by a high-fat diet and STZ injection leads to islet β-cell failure and apoptosis, and ultimately to hypoinsulinemia and hyperglycemia (39). This is similar to the present method of T2DM model establishment, and closely mimics the natural history and metabolic characteristics of late stage T2DM. T2DM is characterized by an increase in IR in conjunction with the inability of islet β-cells to secrete sufficient insulin to compensate. IR and hypoinsulinemia may result in a hyperglycemic state that is a major risk factor for the development of diabetes-induced liver complications. Hyperglycemia promotes the accumulation of fat in the liver, while releases oxidizing and inflammatory mediators and causing local and systemic damage. In the present study, the administration of vitamin D reduced the FPG and increased the FINS. These changes are in accordance with a prior study (40) which showed that vitamin D is able to act on β-cells through the vitamin D response elements present in insulin gene promoter, thereby increasing the levels of FINS in plasma which may result in decreased FBG levels in vitamin D-treated group. In addition, the immunomodulatory properties of vitamin D may decrease the release of inflammatory cytokines such as TNF-α and IL-1β, while improving IR-induced by inflammation, thereby restoring residual β-cells and decreasing FPG induced by IR.

In summary, the present results indicate the protective effects of vitamin D against diabetes-induced liver complications, which may occur by modulating the inflammatory response, attenuating the crosstalk between inflammation and IR and ameliorating hyperglycemic state. The results suggest an association between vitamin D, inflammation and T2DM.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81160116).

References

1. Guadarrama-López AL, Valdés-Ramos R and Martinez-Carrillo BE: Type 2 diabetes, PUFAs, and vitamin D: Their relation to inflammation. J Immunol Res 2014: 860703, 2014.
2. Flores M: A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev 18: 175-182, 2005.
3. Chiu KC, Chu A, Go VL and Saad MF: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79: 820-825, 2004.
4. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE and Hu FB: Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29: 650-656, 2006.
5. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
6. Gregor MF and Hotamisligil GS: Inflammatory mechanisms in obesity. Ann Rev Immunol 29: 415-445, 2011.
7. Sattar N, McCoyre DW, Capell H and McInnes IB: Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963, 2003.
8. Knobler H, Zbornicky T, Sandler A, Haran N, Ashur Y and Schattner A: Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-disease association. Am J Gastroenterol 98: 2751-2756, 2003.

9. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R and Mathieu C: Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 77: 47-57, 2007.

10. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Paledza G and Arcaro G: Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17: 517-524, 2007.

11. Laskin DL, Weinberger B and Laskin JD: Functional heterogeneity in liver and lung macrophages. J Leukoc Biol 70: 163-170, 2001.

12. Korf H, Wenes M, Stijlemans B, Takishi T, Robert S, Miani M, Ezirik DL, Gysemans C and Mathieu C: 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 217: 1192-1200, 2012.

13. Alroy I, Towers TL and Freedman LP: Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFAT/Ap-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 15: 5789-5799, 1995.

14. Ip Y and Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10: 205-219, 1998.

15. Karin M and Gallagher E: From JNK to pay dirt: Jun kinases, NFAT/p300 and vitamin D, inflammation and type 2 diabetes. Nutrients 4: 52-67, 2012.

16. Kaneto H, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsushita M, Yamasaki Y and Hori M: Modulation of the JNK pathway in liver affects insulin resistance status. J Biochem 279: 45803-45809, 2004.

17. Yang R and Trevillyan JM: c-Jun N-terminal kinase pathways in diabetes. Int J Biochem Cell Biol 40: 2702-2706, 2008.

18. Sharfi H and Eldar-Finkelman H: Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab 294: E307-E315, 2008.

19. Kaneto H: The JNK pathway as a therapeutic target for diabetes. Expert Opin Ther Targets 9: 581-592, 2005.

20. Tarantino G and Caputi A: JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 17: 3785-3794, 2011.

21. Chagas CE, Borges MC, Martini LA and Rogero MM: Focus on inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 17: 3785-3794, 2011.

22. Tempone M, Falezza G and Arcaro G: Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17: 517-524, 2007.